Infection by *Mycobacterium tuberculosis* (MTB) remains a major public health problem in the world. In this respect, tuberculosis (TB) is the second cause of death after human immunodeficiency virus (HIV) infection and is the most common cause of death of people infected with HIV ([@B8], [@B6]).

Most MTB-infected individuals remain asymptomatic, with a small proportion of them eventually progressing to active TB disease. Therefore, they may become a reservoir of *Mycobacterium* and this may constitute an obstacle to its eradication. The most common manifestation of TB is a chronic pulmonary disease and immunocompromised individuals are the most prone to developing symptomatic disease ([@B20], [@B33]).

The diagnosis of latent MTB infection remains a challenge. The tuberculin skin test (TST), also known as the purified protein derivative (PPD) skin test, is still largely employed as a diagnostic tool, but it has shown low specificity, as it often displays antigenic cross-reactivity with unrelated microorganisms ([@B11]). The tests that measure interferon (IFN)-γ production, IFN-γ release assays (IGRA), were developed to detect latent TB and are based upon the detection of IFN-γ produced specifically from peptides identified during infection with MTB; they are considered to be more specific than TST for the diagnosis of *Mycobacterium* infection. One of these tests, the enzyme-linked immunospot (ELISPOT) assay, was shown to have a better diagnostic performance when compared with TST ([@B13], [@B14], [@B7]). The ELISPOT assay is closely correlated with the exposure of the individual to *Mycobacterium*([@B13]) and shows less indeterminate results than TST tests ([@B12]).

A peptide-based IGRA test could offer several advantages, including the precise knowledge of the antigen specificity. However, such peptides should be widely recognised by the population to be tested. Until recently, the available tools for searching immunodominant epitopes was the direct testing of substantial numbers of overlapping peptides or peptide libraries. The identification of major histocompatibility complex-binding motifs allowed the prediction of potential T-cell epitopes ([@B27]) and such motifs were found to cluster in certain protein regions ([@B25]). The TEPITOPE algorithm predicts binding to 25 distinct human leukocyte antigen (HLA)-DR molecules based on quantitative matrices established from HLA-DR binding assays ([@B34], [@B5], [@B22], [@B16], [@B17], [@B9]). This advance lead to the selection of sequences enriched for high affinity-binding peptides, those with the highest chance of eliciting effective T-cell responses against immunogens ([@B30]). Additionally, TEPITOPE also allows for the detection of sequences predicted to bind to several HLA-DR molecules simultaneously, opening the possibility of selecting promiscuous T-cell epitopes. Another advantage of the peptide-based IGRA test is the ability to test individual peptides, allowing for the analysis of peptide-specific T cell responses as well as peptide pools.

Therefore, to identify the frequently recognised immunodominant epitopes of three immunogenic proteins of MTB, we used the TEPITOPE algorithm to screen GroEL-2 ([@B31], [@B15]), phosphate-binding protein 1 precursor (PBP-1) ([@B1]) and 19 kDa antigen ([@B2], which are proteins that were previously found to elicit potentially strong immunological responses ([@B36], [@B24], [@B26], [@B37], for multiple HLA-DR binding sequences, in a group of healthy individuals. Synthetic peptides encoding such potential CD4^+^ T cell epitopes were used in IFN-γ ELISPOT assays with peripheral blood mononuclear cells (PBMCs) of TST-positive and TST-negative Brazilian healthy subjects.

SUBJECTS, MATERIALS AND METHODS
===============================

*Subjects* - The sample comprised 32 Brazilian healthy volunteers (donors) selected from students and workers from the Advanced Laboratory of Public Health, Oswaldo Cruz Foundation (Fiocruz), Salvador, state of Bahia, Brazil, and the Immunology Laboratory, Heart Institute, University of São Paulo (USP), São Paulo, state of São Paulo, Brazil. All donors received Bacille Calmette-Guérin (BCG) vaccination during childhood. The mean age of the 32 donors was 32 ± 9 years. They were divided into two groups according to the TST response: latent MTB infection (16 subjects, TST-positive) and uninfected controls (16 subjects, TST-negative), with a mean age of 35 ± 11 years (TST-positive) or 30 ± 7 years (TST-negative). The TST was performed according to the Mantoux method with PPD, following the manufacturer's instructions (Statens Serum Institute, Denmark). TST was considered positive when the induration was ≥ 10 mm after 48 h of PPD application. All of the individuals gave their written informed consent to participate in this study, which was approved by the Institutional Review Boards of the School of Medicine, USP (protocol 250/04) and Fiocruz (protocol 51/2004).

*Peptide selection -*Sequences of three important antigens expressed by MTB were used: GroEL2 protein, accession P9WPE6.1 ([@B15]), PBP-1, accession P9WGU0.1 ([@B1]) and 19 kDa antigen, accession S02753 ([@B2]. These sequences were screened by TEPITOPE and we predicted seven epitopes that were used in the ELISPOT assay. The seven peptides were predicted to bind to at least 12 out of the 25 HLA-DR molecules in the TEPITOPE matrix, as previously described ([@B5]. They correspond to an inner nonamer core selected as the HLA-binding motif with flanking amino acids added when possible (e.g., conserved flanking sequences) at either or both the N and C-terminal ends, to increase the efficiency of in vitro peptide presentation to CD4^+^ T cells ([@B5], [@B17].

*Peptide synthesis* - Peptides of the MTB proteins were synthesised by solid phase technology using 9-fluorenylmethoxycarbonyl strategy, with the C-terminal carboxyl group in amide form. Peptide purity and quality were assessed by reverse-phase high performance liquid chromatography and mass spectrometry, as described elsewhere ([@B3]). The peptides were dissolved in dimethyl sulfoxide (DMSO) for stock solutions of 25 mg/mL.

*PBMC separation* - PBMC suspensions were prepared from 50 mL heparinised venous blood by density gradient centrifugation using Ficoll-Hypaque, 1.077 g/L (Pharmacia, Sweden). The cells were washed twice with phosphate-buffered saline (PBS) (Gibco, UK) and were kept frozen at -196ºC in liquid nitrogen in foetal calf serum (FCS) containing 10% DMSO (Merck, Germany) until testing. After thawing, the PBMCs were suspended in RPMI-1640 (Gibco), supplemented with 200 mM glutamine, 100 U/mL penicillin, 100 U/mL streptomycin and 10% FCS, 100 mM non-essential amino acids and 100 mM pyruvate.

*IFN-γ ELISPOT assays* - The IFN-γ ELISPOT assay was performed as described previously ([@B35], [@B18], [@B39], [@B38]). Briefly, cryopreserved PBMCs (10^5^ cells/well) were incubated with 5 μM of each peptide on a 96-well MultiScreen ELISPOT plate (Multiscreen MAIPS4510; Millipore, USA) previously coated with 50 μL/well of capture anti-human IFN-γ monoclonal antibody (mAb) diluted 1/1,000 (IgG1/B-B1; Diaclone, France) in PBS (1 μL/mL of mAb) at 4ºC overnight. The plates were washed three times with PBS. The remaining peptide binding sites were blocked with 100 μL RPMI/10% FCS for 2 h at 37ºC. The medium was removed just before the addition of cell suspensions (100 μL) and stimulating agents (100 μL). The MTB peptides (5 μM) were added to each well of the plates. The plates were incubated for 20 h at 37ºC in 5% CO~2~. PBMCs incubated with 0.5 μg/mL phytohemagglutinin (Sigma, France) or RPMI/10% FCS served as the positive and negative controls, respectively. At the end of the incubation, the cells were removed from the ELISPOT plates by washing nine times: three times with PBS, three times with PBS containing 0.05% Tween-20 (Sigma) and three times again with PBS. Spots were detected after the addition of the second biotinylated anti-human IFN-γ mAb (B-G1; Diaclone) (100 μL/well, 4 h, 37ºC in 5% CO~2~), diluted 1/500 in PBS-bovine serum albumin (PBS-BSA) (Gibco) (1 μL/500 μL of biotinylated antibody). The plates were washed three times with PBS, followed by streptavidin-alkaline phosphatase conjugate (Amersham, France) (100 μL/well, 1 h, 37ºC in 5% CO~2~) diluted 1/1000 in PBS-BSA (1 μL/mL of streptavidin-alkaline phosphatase conjugate), washed three times with PBS and incubated with 50 μL/well of chromogen substrates 5-bromo-4-chloro-3-indolyl-phosphate toluidine and 4-nitroblue tetrazolium (Sigma), which were incubated at room temperature (25ºC) until the appearance of violet spots (\~ 30 min). The plates were washed with tap water and dried overnight. Antigen-specific T cells, expressed as spot forming cells (SFC)/10^6^ PBMCs frequencies, were measured using an automated stereomicroscope (KS ELISPOT; Carls Zeiss, Germany). The SFC number was calculated after subtracting the negative control values (wells with cells in the absence of peptide) from the same subject. The positivity cut-off was ≥ 30 IFN-γ SFC/10^6^ PBMCs, which was above the mean ± 3 standard deviation of the highest response found among all uninfected control subjects to any peptide (data not shown). The magnitude of response to each given peptide or the sum of the SFC of the total peptides was calculated as the SFC/10^6^PBMCs of peptides with responses above the positivity cut-off.

*Statistical analysis* - Statistical analysis was performed using the GraphPad Prism package v.3.0. Comparisons of the number of IFN-γ SFC/10^6^ PBMCs between the clinical groups were performed with a non-parametric one-way ANOVA, Kruskal-Wallis and Dunn's Test. The Mann-Whitney *U* test was used to calculate the differences between the groups. Values of p \< 0.05 were considered significant.

RESULTS
=======

Three MTB antigenic proteins, GroEL2, PBP-1 and 19 kDa, were scanned with the TEPITOPE algorithm at a 3% threshold. Seven peptide sequences predicted to bind to multiple HLA-DR molecules were synthesised ([Table I](#t1){ref-type="table"}).

TABLE ISequences of peptides derived from *Mycobacterium tuberculosis*(MTB) sequences selected by TEPITOPE algorithmPeptideHLA-DR molecules predicted to bind to peptide^*a*^ (%)SequenceGroEL2 (215-229)76DPYILLVSSKVSTVKGroEL2 (463-477)60AEKVRNLPAGHGLNAPBP-1 (59-75)84TLLYPLFNLWGPAFHERPBP-1 (118-133)88KGLMNIALAISAQQVNPBP-1 (351-365)64QVHFQPLPPAVVKLSPBP-1 (352-371)84VHFQPLPPAVVKLSDALIAT19 kDa (127-141)48GSHYKITGTATGVDM[^1]

Next, we tested if the IFN-γ response to the seven peptides could discriminate between TST-positive and TST-negative healthy donors. The mean size (± standard deviation) of PPD induration detected for TST-negative individuals was 0.71 ± 2.02 mm and for TST-positive individuals was 11.14 ± 4.07 mm. PBMCs from the 16 TST-positive and 16 TST-negative individuals were tested in the presence of each peptide for an IFN-γ ELISPOT assay. The T cell responses are shown in [Table II](#t2){ref-type="table"}. The frequency of peptide recognition by the TST-positive group was significantly higher than the TST-negative group. Eighty-eight percent (14 out of 16 donors) of TST-positive donors recognised at least one peptide and 31% (5 out of 16 donors) had responses to three or more peptides, while in the TST-negative group, 31% (5 out of 16 donors) responded to any peptides and only 12% (2 out of 16 donors) responded to three or more peptides (p = 0.002) ([Fig. 1](#f01){ref-type="fig"}).

TABLE IIRecognition of human leukocyte antigen (HLA)-DR promiscuous epitopes from *Mycobacterium tuberculosis*antigens by peripheral blood mononuclear cells (PBMC) from tuberculin skin test (TST)-positive and TST-negative subjects using the interferon (IFN)-γ ELISPOT assayPeptidesIFN-γ SFC/10^6^PBMC (n)TST-positiveTST-negativeP1P2P3P4P5P6P7P8P9P10P11P12P13P14P15P16N1N2N3N4N5N6N7N8N9N10N11N12N13N14N15N16PBP-1 (59-75)0**405560**0**55**2500723200**65**0**100**00000010310153**30**270720PBP-1 (118-133)**30**10**155**0000**30**013101767250**60**00005010301037**8743**2710PBP-1 (351-365)**6030140230**002500230712750**40**15**30**200005735200**83**23**50**27PBP-1 (352-371)2010**13560**200000**37**7**30183**52030**95**5100510701072020**4050**7GroEL2 (215-229)40**303580**50000**30503330**0**40**05**30**50005170527032307GroEL2 (463-477)**4060110130**250050132317**37**025**30**0050055720101000017019 kDa (127-141)**55**10**95**102010**40**051023**13123**05**37**025000001317151301723**37**0Peptides recognised54750111021261150300000000012220Sum of spots225160725560055403006750635676540267015500000000030170831370[^2]

Fig. 1: number of *Mycobacterium tuberculosis* (MTB) peptides recognised by tuberculin skin test (TST)-positive (TST+) and TST-negative (TST-) donors. Peripheral blood mononuclear cells (PBMCs) from 16 TST-positive and 16 TST-negative healthy donors were assayed with seven human leukocyte antigen-DR promiscuous peptides derived from MTB protein sequences. Each peptide was tested individually at concentration of 5 µM and the number of spot forming cells (SFC) interferon-γ/106 PBMC were calculated according to the following equation: (average spots in duplicate peptide wells - average spots in duplicate control wells) x 5. Positive responses were ≥ 30 SFC/106 PBMC. The columns represent the number of TST-positive and TST-negative donors tested that were negative or able to show positive responses in the ELISPOT assay in response to different numbers of peptides (p = 0.01, Mann-Whitney *U* test).

Each of the selected peptides induced IFN-γ production by PBMCs from at least 31% of the TST-positive donors. The frequency of responders to individual peptides ranged from 31% to PBP-1 (118-133), PBP-1 (352-371) and 19 kDa (127-141) to 56% to GroEL2 (215-229) ([Fig. 2](#f02){ref-type="fig"}). In contrast, among TST-negative donors, there was no response to GroEL2 (463-477) peptide and the most frequently recognised peptides were PBP-1 (351-365) and PBP-1 (352-371), with 19% of responders.

Fig. 2: proportion of tuberculin skin test (TST)-positive (TST+) and TST-negative (TST-) donors that recognised selected *Mycobacterium tuberculosis* (MTB) peptides. Peripheral blood mononuclear cells (PBMCs) from 16 TST-positive and 16 TST-negative healthy donors were tested with seven MTB derived peptides and the spot forming cells interferon-γ/106 PBMC were calculated. The columns represent the proportion of TST-positive and TST-negative individuals that recognised at list one peptide (p = 0.001, Mann-Whitney *U* test).

The magnitude of responses to the peptides (sum of IFN-γ SFC of all peptides with positive responses) was higher in the TST-positive group than in the TST-negative group ([Fig. 3](#f03){ref-type="fig"}). The total number of IFN-γ SFC in response to MTB peptides was 182 ± 230 SFC/10^6^PBMCs among the TST-positive donors, compared to 36 ± 62 SFC/10^6^PBMCs in the TST-negative donors (p = 0.007). The magnitude of the responses per individual ranged from 0-725 SFC/10^6^PBMCs among the TST-positive individuals and 0-170 SFCs/10^6^ PBMCs among the TST-negative individuals ([Table II](#t2){ref-type="table"}).

Fig. 3: magnitude of responses to *Mycobacterium tuberculosis*peptides. The bars represent the magnitude of response of each peptide (overall sum of spots of all individuals with positive responses). Positive responses \> 30 spot forming cells (SFC) interferon (IFN)-γ/106 peripheral blood mononuclear cells (PBMCs) (p = 0.007, Mann-Whitney *U* test). TST+: tuberculin skin test-positive; TST-: TST-negative.

The PBP-1 (351-365) MTB peptide induced the highest magnitude of response, 627 SFC/10^6^PBMCs, followed by PBP-1 (352-371), with 446 SFC/10^6^PBMCs ([Fig. 3](#f03){ref-type="fig"}). In the TST-negative group, the highest magnitude of response was to PBP-1 (352-371), with 185 SFC/10^6^PBMCs. In addition, a response to GroEL2 (463-477) was observed only in the TST-positive group (p = 0.02).

Taking into consideration that all 32 healthy donors were subjected to BCG vaccination, the combination of TST and positivity at the IFN-γ ELISPOT test raised the overall positivity value from 50% (16/32) to 59% (19/32) for recognition of*MTB* antigens.

DISCUSSION
==========

Our results suggest that the peptides predicted by TEPITOPE are able to identify a significant number of individuals with latent MTB infection. Moreover, in our study, the use of these peptides allowed us to identify individuals with latent MTB infection not tracked by the TST test.

The TEPITOPE is an algorithm that uses a matrix that predicts the binding of 25 HLA-DR molecules. This allows the identification of epitopes with high binding affinity and the ability to generate a strong T cell response. The use of this algorithm can lead to the identification of a greater number of epitopes, which would display a higher sensitivity and specificity for detecting MTB, as reported elsewhere ([@B40]).

The two methods used in this study to assess latent MTB infection, the TST and the IFN-γ ELISPOT, showed similar results in 88% of the evaluated individuals who were TST-positive. These findings are similar to the published data, in which there is a higher correlation of IGRA tests and TB when compared to TST and TB ([@B4], [@B19], [@B28]). Furthermore, it was possible to identify TST-negative individuals (31%) who responded to peptides predicted by TEPITOPE. In this respect, [@B13] reported that ELISPOT offers a more accurate approach than TST for the identification of individuals who have latent TB infection and could improve TB control by more precise targeting of preventive treatment. However, possible antigenic cross-reactions or non-specific responses cannot be excluded and should be addressed. The advantage of using the IGRA with seven promiscuous peptides is that would ensure larger number of responder individuals independent of HLA class II and also a greater range or a greater number of recognised peptides.

To date, no fully effective methodology is available that can unequivocally differentiate individuals who actually have latent MTB infection from those who were BCG vaccinated or even those that have active MTB infection. The most widely and currently used test for the screening of latent MTB infection remains the TST because it is considered a low cost point-of-care-test ([@B13], [@B10], [@B32]). Therefore, it remains the method of choice for screening for latent MTB infection, primarily due to a better cost/benefit ratio when compared to tests based on IGRA ([@B23]).

[@B29] report that immunocompromised persons infected with MTB have a high occurrence of false-negative results in the TST and, in such cases, they recommend to tailor the application of IGRA assays for latent MTB infection in different high-risk groups and advise caution in their use in immunosuppressed patients.

The results of the TST may show false positive results in individuals previously immunised with BCG or because the population of the study has high rates of exposure to MTB ([@B32]). Another relevant aspect is that 70-80% of individuals with pulmonary TB have a diameter of the induration greater than 10 mm by TST and this value is reduced in individuals co-infected with HIV-1 ([@B21]). This combination of novel MTB CD4^+^ T-cell epitopes should be tested in a larger cohort of individuals with latent TB to confirm its potential to discriminate latent MTB infection from no TB infection and may be included in ELISPOT-based IFN-γ response assays to identify individuals with such conditions.
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[^1]: *a*: 3% threshold; HLA: human leukocyte antigen.

[^2]: SFC/10^6^PBMC were calculated according to the following equation: (average spots in duplicate peptide wells - average spots in duplicate control wells) x 5. Positive responses (≥ 30 SFC/10^6^PBMC) are highlighted by a gray background.
